Lack of association between the norepinephrine transporter gene and major depression in a Han Chinese population

Journal of Psychiatry and Neuroscience

Volumn 32, Issue 2, 2007, Pages 121-128

  Chang, Chuan Chia ^a   Lu, Ru Band ^b   Chen, Chih Lun ^a   Chu, Chi Ming ^a   Chang, Hsin An ^a   Huang, Cheng Chang ^a   Huang, Yi Lin ^a   Huang, San Yuan ^a  

^a TRI SERVICE GENERAL HOSPITAL   (Taiwan)

^b NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

Author keywords

Major depression; Norepinephrine transporter gene; Polymorphisms; Subtypes of major depression

Indexed keywords

NORADRENALIN TRANSPORTER;

ADOLESCENT; ADULT; AGED; ARTICLE; CHINESE; CONTROLLED STUDY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; EXON; FAMILY HISTORY; FEMALE; GENE FREQUENCY; GENETIC HETEROGENEITY; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; MAJOR AFFECTIVE DISORDER; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; POLYMERASE CHAIN REACTION;

EID: 34247151065     PISSN: 11804882     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. Bunney WE Jr, Davis JM. Norepinephrine in depressive reactions. A review. Arch Gen Psychiatry 1965;13:483-94.
2. Prange AJ Jr, Wilson IC, Lynn CW, et al. L-tryptophan in mania. Contribution to a permissive hypothesis of affective disorders. Arch Gen Psychiatry 1974;30:56-62.
3. Schildkraut JJ. The catecholamine hypothesis of affective disorders: a review of supporting evidence. Am J Psychiatry 1965;122: 509-22.
4. Martensson B, Wagner A, Beck O, et al. Effects of clomipramine treatment on cerebrospinal fluid monoamine metabolites and platelet 3H-imipramine binding and serotonin uptake and concentration in major depressive disorder. Acta Psychiatr Scand 1991;83: 125-33.
5. Sheline Y, Bardgett ME, Csernansky JG. Correlated reductions in cerebrospinal fluid 5-HIAA and MHPG concentrations after treatment with selective serotonin reuptake inhibitors. J Clin Psychopharmacol 1997;17:11-4.
6. De Bellis MD, Geracioti TD Jr, Altemus M, et al. Cerebrospinal fluid monoamine metabolites in fluoxetine-treated patients with major depression and in healthy volunteers. Biol Psychiatry 1993;33:636-41.
7. Katz MM, Maas JW, Frazer A, et al. Drug-induced actions on brain neurotransmitter systems and changes in the behaviors and emotions of depressed patients. Neuropsychopharmacology 1994;11:89-100.
8. Delgado PL, Miller HL, Salomon RM, et al. Monoamines and the mechanism of antidepressant action: effects of catecholamine depletion on mood of patients treated with antidepressants. Psychopharmacol Bull 1993;29:389-96.
9. Miller HL, Delgado PL, Salomon RM, et al. Clinical and biochemical effects of catecholamine depletion on antidepressant-induced remission of depression. Arch Gen Psychiatry 1996;53:117-28.
10. Uhl GR, Johnson PS. Neurotransmitter transporters: three important gene families for neuronal function. J Exp Biol 1994;196:229-36.
11. Amara SG, Kuhar MJ. Neurotransmitter transporters: recent progress. Annu Rev Neurosci 1993;16:73-93.
12. Beique JC, Lavoie N, de Montigny C, et al. Affinities of venlafaxine and various reuptake inhibitors for the serotonin and norepinephrine transporters. Eur J Pharmacol 1998;349:129-32.
13. Andreoli V, Caillard V, Deo RS, et al. Reboxetine, a new noradrenaline selective antidepressant, is at least as effective as fluoxetine in the treatment of depression. J Clin Psychopharmacol 2002;22:393-9.
14. Ferguson JM, Wesnes KA, Schwartz GE. Reboxetine versus paroxetine versus placebo: effects on cognitive functioning in depressed patients. Int Clin Psychopharmacol 2003;18:9-14.
15. Massana J, Moller HJ, Burrows GD, et al. Reboxetine: a double-blind comparison with fluoxetine in major depressive disorder. Int Clin Psychopharmacol 1999;14:73-80.
16. Klimek V, Stockmeier C, Overholser J, et al. Reduced levels of norepinephrine transporters in the locus coeruleus in major depression. J Neurosci 1997;17:8451-8.
17. Brüss M, Kunz J, Lingen B, et al. Chromosomal mapping of the human gene for the tricyclic antidepressant-sensitive noradrenaline transporter. Hum Genet 1993;91:278-80.
18. Pörzgen P, Bönisch H, Brüss M. Molecular cloning and organization of the coding region of the human norepinephrine transporter gene. Biochem Biophys Res Commun 1996;227:642-3.
19. Stöber G, Nöthen MM, Pörzgen P, et al. Systematic search for variation in the human norepinephrine transporter gene: identification of five naturally occurring missense mutations and study of association with major psychiatric disorders. Am J Med Genet 1996;67:523-32.
20. Sand PG, Mori T, Godau C, et al. Norepinephrine transporter gene (NET) variants in patients with panic disorder. Neurosci Lett 2002; 333:41-4.
21. Zill P, Engel R, Baghai TC, et al. Identification of a naturally occurring polymorphism in the promoter region of the norepinephrine transporter and analysis in major depression. Neuropsychopharmacology 2002;26:489-93.
22. Kim CH, Kim HS, Cubells JF, et al. A previously undescribed intron and extensive 5′ upstream sequence, but not Phox2a-mediated transactivation, are necessary for high level cell type-specific expression of the human norepinephrine transporter gene. J Biol Chem 1999;274:6507-18.
23. Meyer J, Wiedemann P, Okladnova O, et al. Cloning and functional characterization of the human norepinephrine transporter gene promoter. J Neural Transm 1998;105:1341-50.
24. Lander ES, Schork NJ. Genetic dissection of complex traits. Science 1994;265:2037-48.
25. Endicott J, Spitzer RL. A diagnostic interview: the schedule for affective disorders and schizophrenia. Arch Gen Psychiatry 1978;35: 837-44.
26. Merikangas KR, Stevens DE, Fenton B, et al. Co-morbidity and familial aggregation of alcoholism and anxiety disorders. Psychol Med 1998;28:773-88.
27. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th ed. Washington, DC: American Psychiatric Press; 1994.
28. Huang SY, Lin WW, Ko HC, et al. Possible interaction of alcohol dehydrogenase and aldehyde dehydrogenase genes with the dopamine D2 receptor gene in anxiety-depressive alcohol dependence. Alcohol Clin Exp Res 2004;28:374-84.
29. Buchner A, Faul F, Erdfelder E. G-power: a priori, post hoc, and compromise power analyses for the Macintosh, version 2.1.1. Trier: University of Trier; 1996.
30. Xie X, Ott J. Testing linkage disequilibrium between a disease gene and maker loci. Am J Hum Genet 1993;53(Suppl):1107.
31. Yoshida K, Takahashi H, Higuchi H, et al. Prediction of antidepressant response to milnacipran by norepinephrine transporter gene polymorphisms. Am J Psychiatry 2004;161:1575-80.
32. Inoue K, Itoh K, Yoshida K, et al. Positive association between T-182C polymorphism in the norepinephrine transporter gene and susceptibility to major depressive disorder in a japanese population. Neuropsychobiology 2004;50:301-4.
33. Ryu SH, Lee SH, Lee HJ, et al. Association between norepinephrine transporter gene polymorphism and major depression. Neuropsychobiology 2004;49:174-7.
34. Owen D, Du L, Bakish D, et al. Norepinephrine transporter gene polymorphism is not associated with susceptibility to major depression. Psychiatry Res 1999;87:1-5.
35. Jönsson EG, Nöthen MM, Gustavsson JP, et al. Polymorphisms in the dopamine, serotonin, and norepinephrine transporter genes and their relationships to monoamine metabolite concentrations in CSF of healthy volunteers. Psychiatry Res 1998;79:1-9.
36. Kidd KK. Associations of disease with genetic markers: deja vu all over again. Am J Med Genet 1993;48:71-3.
37. Lu RB, Lin WW, Lee JF, et al. Neither antisocial personality disorder nor antisocial alcoholism is associated with the MAO-A gene in Han Chinese males. Alcohol Clin Exp Res 2003;27:889-93.
38. Hsu YP, Loh EW, Chen WJ, et al. Association of monoamine oxidase A alleles with alcoholism among male Chinese in Taiwan. Am J Psychiatry 1996;153:1209-11.
39. Duggan C, Sham P, Minne C, et al. Family history as a predictor of poor long-term outcome in depression. Br J Psychiatry 1998;173: 527-30.
40. Eccleston D, Scott J. Treatment, prediction of relapse and prognosis of chronic primary major depression. Int Clin Psychopharmacol 1991;6(Suppl 2):3-10.
41. Klein DN, Schatzberg AF, McCullough JP, et al. Age of onset in chronic major depression: relation to demographic and clinical variables, family history, and treatment response. J Affect Disord 1999;55:149-57.
42. Zisook S, Rush AJ, Albala A, et al. Factors that differentiate early vs. later onset of major depression disorder. Psychiatry Res 2004; 129:127-40.
43. Kessler RC, Nelson CB, McGonagle KA, et al. Comorbidity of DSM-III-R major depressive disorder in the general population: results from the US National Comorbidity Survey. Br J Psychiatry 1996;30(Suppl):17-30.
44. Kessler RC, Berglund P, Demler O, et al. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA 2003;289:3095-105.
45. Gonzalez-Maeso J, Rodriguez-Puertas R, Meana JJ, et al. Neurotransmitter receptor-mediated activation of G-proteins in brains of suicide victims with mood disorders: selective supersensitivity of alpha(2A)-adrenoceptors. Mol Psychiatry 2002;7:755-67.
46. Ordway GA, Schenk J, Stockmeier CA, et al. Elevated agonist binding to alpha2-adrenoceptors in the locus coeruleus in major depression. Biol Psychiatry 2003;53:315-23.
47. Maes M, Van Gastel A, Delmeire L, et al. Decreased platelet alpha-2 adrenoceptor density in major depression: effects of tricyclic antidepressants and fluoxetine. Biol Psychiatry 1999;45:278-84.
48. Garcia-Sevilla JA, Ventayol P, Perez V, et al. Regulation of platelet alpha 2A-adrenoceptors, Gi proteins and receptor kinases in major depression: effects of mirtazapine treatment. Neuropsychopharmacology 2004;29:580-8.